Last mentioned: Mar 4, 2026
FDA Commissioner Marty Makary is reportedly attempting to hire Dr. Tracy Beth Hoeg to lead a new initiative focused on antidepressant safety. The move is tied to a proposed 'bold new warning' for SSRIs and SNRIs, potentially addressing persistent side effects that have long been a point of contention between regulators and the pharmaceutical industry.
A high-ranking FDA official is reportedly attempting to recruit Dr. Tracy Beth Hoeg, a vocal advocate for stricter antidepressant warnings, to a key agency role. The move signals a potential shift in how the FDA evaluates long-term psychiatric drug risks and has raised internal concerns regarding hiring protocols.
A senior FDA official's attempt to hire Dr. Tracy Beth Hoeg, a vocal advocate for stricter antidepressant warnings, has sparked debate over regulatory independence. The move could signal a more aggressive approach to drug safety labeling for common psychiatric medications, impacting pharmaceutical compliance and litigation risk.